“Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s240. doi:10.25251/skin.7.supp.240.